CAS: 25122-57-0; (8S,9R,10S,13S,14S,16S,17R)-17-(2-Chloroacetyl)-9-Fluoro-10,13,16-Trimethyl-3,11-Dioxo-6,7,8,9,10,11,12,13,14,15,16,17-Dodecahydro-3H-Cyclopenta[a]Phenanthren-17-Yl Butyrate

上下游产品

butanoic acid anhydride clobetasone

反应生成丁酸倍氯他松
参考文献:Investigations On The Polymorphism And Pseudopolymorphism Of Clobetasone Butyrate
标题:Investigations On The Polymorphism And Pseudopolymorphism Of Clobetasone Butyrate
摘要:对丁酸氯倍他松的多态性和假多态性进行了研究.溶剂介导转化实验表明,市售的 I 型丁酸氯倍他松在室温下是热力学上最稳定的形态,Dsc 测量结果表明,它在熔化前也应该是最稳定的形态.I 型在空间群 P212121 中结晶,有三个在晶体学上独立的分子,具有相似的构象.从甲醇中又发现了一种假多晶型.在晶体结构(空间群 P212121)中,溶剂分子通过 O-H-O 氢键与丁酸氯倍他松分子相连.使用热重分析法,差示热分析法和差示扫描量热法对溶解物进行的研究证明,去除溶剂后会得到一种无定形形式,进一步加热后会结晶成形式 I.
Doi:10.1135/cccc2011027

专利信息

专利号:US-9051302-B2
优先权日:2008-01-15
标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents
发明人：WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN
权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG
摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

专利号:US-2013035307-A1
优先权日:2010-01-26
标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
发明人：PRESTWICH GLENN D; KENNEDY THOMAS P
权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

专利号:WO-2023096715-A9
优先权日:2021-10-22
标 题:Immunomodulatory glycosphingolipids and methods of use thereof
发明人：KASPER DENNIS; OH SUNGWHAN
权利人:HARVARD COLLEGE
摘要:Provided herein are a subset of alpha-galactosylceramide (alpha-GC) compounds having improved immunomodulatory activity, particularly with respect to NKT cell number and activity. Also provided herein are methods of use of such compounds, including in the modulation of NKT cells and/or activity in vivo. Further provided are combinatorial synthesis methods for generating alpha-GC compounds of specifically defined structure and thereby generating pure preparations thereof.

专利号:KR-20230058630-A
优先权日:2020-07-28
标题 :Chiral synthesis of fused bicyclic RAF inhibitors

专利号:US-2022125838-A1
优先权日:2019-02-11
标题 :Immunomodulatory glycosphingolipids and methods of use thereof
发明人：OH SUNGWHAN; KASPER DENNIS L; SONG HEEBUM; PARK SEUNG BUM
权利人:HARVARD COLLEGE; SEOUL NAT UNIV R&DB FOUNDATION
摘要:Provided herein are a subset of alpha-galactosylceramide (alpha-GC) compounds having improved immunomodulatory activity, particularly with respect to NKT cell number and activity. Also provided herein are methods of use of such compounds, including in the modulation of NKT cells and/or activity in vivo. Further provided are combinatorial synthesis methods for generating alpha-GC compounds of specifically defined structure and thereby generating pure preparations thereof.

专利号:US-12304912-B2
优先权日:2020-07-28
标 题 :Fused bicyclic RAF inhibitors and methods for use thereof
发明人：BELFIELD ANDREW; JONES CLIFFORD DAVID; MARGATHE JEAN-FRANÇOIS; COLLETTO CHIARA
权利人:JAZZ PHARMACEUTICALS IRELAND LTD
摘要:The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.